Cessation Therapeutics

Cessation Therapeutics was founded with a vision of making the company's world addiction free through promoting immunotherapy based biotech innovation. Cessation Therapeutics is developing novel immunotherapy vaccine candidates and small molecules with the objective of helping millions of families overcome the opioid, heroin, morphine, fentanyl, al... cohol and nicotine addiction use disorders. Cessation Therapeutics is currently developing heroin, opioid and fentanyl addiction vaccines based on the technology licensed from The Scripps Research Institute in La Jolla, CA (TSRI) and has commenced planning pre-clinical studies to advance these vaccine candidates into clinical stage. Worldwide, there are more than 26.4 million opioid abusers. It has been estimated that the nonmedical use of opioid pain relievers costs insurance companies up to $72.5 billionannually in health-care costs. The current treatment has a very high relapse rate with long-term success rates of 10 to 25 percent and come with increased risk of side effects and deaths from overdose. There have been more than 70,000 substance abuse/ addiction related deaths. Further, abuse of prescription pain relievers by pregnant women can result in a number of problems in newborns, referred to as neonatal abstinence syndrome (NAS), which has been increasing rapidly since the beginning of the 21st century. In the United States, an estimated 14.4 percent of pregnant women are prescribed an opioid during their pregnancy.Read More